The COMPASS Trial: Net Clinical Benefit of Low-Dose Rivaroxaban Plus Aspirin as Compared With Aspirin in Patients With Chronic Vascular Disease

Rivaroxaban 2.5 mg twice daily plus acetylsalicylic acid (aspirin; ASA) 100 mg reduced the risk of cardiovascular events as compared with ASA monotherapy in the COMPASS trial (Cardiovascular Outcomes for People Using Anticoagulation Strategies) but increased the risk of major bleedings. Analysis of...

Celý popis

Podrobná bibliografia

Vydané v:	Circulation (New York, N.Y.) Ročník 142; číslo 1; s. 40
Hlavní autori:	Steffel, Jan, Eikelboom, John W, Anand, Sonia S, Shestakovska, Olga, Yusuf, Salim, Fox, Keith A A
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	07.07.2020
ISSN:	1524-4539, 1524-4539
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!